NASDAQ:ALNA

Allena Pharmaceuticals - ALNA Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.

Add

Compare

Today's Range: N/A
50-Day Range: $0.02
▼
$0.16
52-Week Range: N/A

Volume: 7.91 million shs
Average Volume: 15.69 million shs
Market Capitalization: $1.95 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.00

About Allena Pharmaceuticals (NASDAQ:ALNA) Stock

Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.

Receive ALNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allena Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ALNA Stock News Headlines

September 29, 2022 | reuters.com

ALNA.O

September 6, 2022 | wsj.com

Firm Retention Summary: Allena Pharmaceuticals Inc.

September 6, 2022 | finance.yahoo.com

Allena Pharmaceuticals Shares Fall After Filing For Bankruptcy

August 11, 2022 | finance.yahoo.com

Allena Pharma Needs To Raise Capital To Continue As A Going Concern

August 11, 2022 | marketwatch.com

Allena Pharmaceuticals Warns of Imminent Funding Need >ALNA

July 19, 2022 | finance.yahoo.com

Allena Pharmaceuticals Announces Completion of Enrollment of Cohorts A and B of ALLN-346 Phase 2a Study 202 in Patients with Gout and Stages 2 and 3 Chronic Kidney Disease

July 12, 2022 | finance.yahoo.com

Allena Pharmaceuticals Announces New Meeting Date and New Record Date for Special Meeting to Approve Reverse Stock Split

July 12, 2022 | finance.yahoo.com

Allena Pharmaceuticals Announces New Meeting Date and New Record Date for Special Meeting to Approve Reverse Stock Split

July 5, 2022 | apnews.com

Allena Pharmaceuticals Announces Rescheduling of Special Meeting to Approve Reverse Stock Split

July 5, 2022 | finance.yahoo.com

Allena Pharmaceuticals Announces Rescheduling of Special Meeting to Approve Reverse Stock Split

July 1, 2022 | uk.investing.com

Why Shares Of Allena Pharmaceuticals Are Skyrocketing Today

June 29, 2022 | investorplace.com

ALNA Stock Alert: What to Know as Allena Pharmaceuticals Soars 200%

May 16, 2022 | msn.com

Short Volatility Alert: Allena Pharmaceuticals

May 12, 2022 | investorplace.com

ALNA Stock Alert: 5 Things to Know as Little-Known Allena Pharmaceuticals Soars 100%

May 12, 2022 | seekingalpha.com

Nano cap stock Allena surges on heavy volume

May 4, 2022 | seekingalpha.com

Allena Pharmaceuticals $2.8M direct offering

May 4, 2022 | finance.yahoo.com

Allena Pharmaceuticals Announces $2.8 Million Registered Direct Offering

March 22, 2022 | seekingalpha.com

Allena downgraded to Neutral at B. Riley citing the end to lead clinical program

March 21, 2022 | finance.yahoo.com

Why Are Allena Pharma Shares Plunging Today

March 21, 2022 | seekingalpha.com

Allena extends losses on plans to end trial for lead asset and financial concerns

March 1, 2022 | finance.yahoo.com

Allena Pharmaceuticals, Inc. (ALNA)

January 29, 2022 | fool.com

Allena Pharmaceuticals, Inc.(ALNA)

January 4, 2022 | finance.yahoo.com

Allena Stock Is Surging In Premarket Today As It Explores Strategic, Financing Alternatives

January 4, 2022 | finance.yahoo.com

Allena Pharmaceuticals Provides Clinical and Corporate Update

November 22, 2021 | finance.yahoo.com

Allena Pharmaceuticals (ALNA) Sees Hammer Chart Pattern: Time to Buy?

See More Headlines

Receive ALNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allena Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ALNA Company Calendar

Last Earnings: 3/31/2022
Today: 12/01/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological Products, Except Diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ALNA
CUSIP: N/A
CIK: 1624658
Web: www.allenapharma.com
Phone: (617) 467-4577
Fax: 617-916-1871
Employees: 35
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $3.00
High Stock Price Forecast: $3.00
Low Stock Price Forecast: $3.00
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-48,660,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -287.46%
Return on Assets: -146.58%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.58
Quick Ratio: 1.58

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.23 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 122,083,000
Free Float: 117,566,000
Market Cap: $1.95 million
Optionable: Not Optionable
Beta: 1.13

Key Executives

Dr. Alexey L. Margolin Ph.D. (Age 69)
Co-Founder & Chairman
Comp: $70k

Dr. Louis Brenner M.B.A. (Age 52)
M.D., Pres, CEO & Director
Comp: $576.86k

Dr. Richard D. Katz (Age 58)
CFO, Principal Financial Officer & Principal Accounting Officer
Comp: $400.67k

Mr. Robert Gallotto (Age 57)
Co-Founder & Strategic Adviser

Mr. Geoffrey A. Swire (Age 49)
Sr. VP of Corp. Devel., Acting COO & Interim Principal Operating Officer

Mr. Hugh Wight
Sr. VP of Technical Operations

Dr. Alicja Januszewicz Ph.D.
VP of People & Culture

Dr. David J. Clark (Age 57)
Chief Medical Officer

Key Competitors

View All Competitors

ALNA Stock - Frequently Asked Questions

Should I buy or sell Allena Pharmaceuticals stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allena Pharmaceuticals in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ALNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALNA, but not buy additional shares or sell existing shares.
View ALNA analyst ratings or view top-rated stocks.
What is Allena Pharmaceuticals' stock price forecast for 2023?: 3 Wall Street analysts have issued 12 month target prices for Allena Pharmaceuticals' shares. Their ALNA share price forecasts range from $3.00 to $3.00. On average, they expect the company's stock price to reach $3.00 in the next year.
View analysts price targets for ALNA or view top-rated stocks among Wall Street analysts.
How were Allena Pharmaceuticals' earnings last quarter?: Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) released its earnings results on Thursday, March, 31st. The company reported ($0.11) earnings per share for the quarter, beating analysts' consensus estimates of ($0.17) by $0.06.
What is Louis Brenner, M.D.'s approval rating as Allena Pharmaceuticals' CEO?: 1 employees have rated Allena Pharmaceuticals Chief Executive Officer Louis Brenner, M.D. on Glassdoor.com. Louis Brenner, M.D. has an approval rating of 100% among the company's employees. This puts Louis Brenner, M.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Allena Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Allena Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), VYNE Therapeutics (VYNE), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), TherapeuticsMD (TXMD), VBI Vaccines (VBIV), Acasti Pharma (ACST) and Miragen Therapeutics (MGEN).
When did Allena Pharmaceuticals IPO?: (ALNA) raised $80 million in an initial public offering on Thursday, November 2nd 2017. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. Credit Suisse, Jefferies and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.
What is Allena Pharmaceuticals' stock symbol?: Allena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNA."
How much money does Allena Pharmaceuticals make?: Allena Pharmaceuticals (NASDAQ:ALNA) has a market capitalization of $0.00.
How can I contact Allena Pharmaceuticals?: Allena Pharmaceuticals' mailing address is ONE NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA, 02462. The official website for the company is www.allenapharma.com. The company can be reached via phone at (617) 467-4577, via email at hannah.deresiewicz@sternir.com, or via fax at 617-916-1871.

This page (NASDAQ:ALNA) was last updated on 12/2/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Allena Pharmaceuticals - ALNA Stock Forecast, Price & News

About Allena Pharmaceuticals (NASDAQ:ALNA) Stock

ALNA Stock News Headlines

ALNA Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

ALNA Stock - Frequently Asked Questions

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info